HCVcc-IN-1
HCVcc-IN-1 is a benzothiazole-2-thiophene S-glycoside derivative with low toxic and antiviral activity.
For research use only. We do not sell to patients.
- CAS No.: 2977251-08-2
- Formula: C29H25BrN2O8S3
- Molecular Weight:705.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
HCVcc-IN-1 (compound 8c) (0.1, 1, 10, and 100 μg/mL; 1 h) shows antiviral activities against a variety of viruses such as coxsackievirus B4 (CBV4), hepatitis A virus HM 175 (HAV), hepatitis C genotype 4 (HCVcc), adenovirus type 7 (HAdV7), and herpes simplex virus 1 (HSV-1) with viral reduction rates of 86.7%, 66.7%, 23.3%, 66.7%, and 36.7%, respectively[1].
HCVcc-IN-1 (0.57-2.0 μg/mL; 1 h) inhibits various virus with IC50 of 0.57 μg/mL (herpes simplex virus), 0.71 μg/mL (HCVcc genotype virus), and 0.69 μg/mL (coxsackievirus B4), respectively; or with CC50 of 2.0 μg/mL (herpes simplex virus), 1.7 μg/mL (HCVcc genotype virus), and 1.7 μg/mL (coxsackievirus B4), respectively[1].
HCVcc-IN-1 (5.16-7.23 μg/mL) inhibits hepatitis C virus NS3/4A and HSV-USP7 protease enzyme with IC50s of 5.16 μg/mL and 7.23 μg/mL[1].
HCVcc-IN-1 (0.01 mM; 24 h) has low cytotoxicity against FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines
-
Concentration:100 μg/mL
-
Incubation Time:24 hours
-
Result:Showed nontoxic under the doses of 100 μg/mL against FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cells, respectively.
Chemical Information
-
CAS No. 2977251-08-2
-
Molecular Weight 705.62
-
Formula C29H25BrN2O8S3
-
SMILES
O=C(C1=C(N)C(C2=NC3=CC=CC=C3S2)=C(S[C@H]4[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@](OC(C)=O)([H])CO4)S1)C5=CC=C(Br)C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HCVcc-IN-1 Related Classifications
HY-151581 Related Classifications
Powered by Bioz